• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[吡喹酮治疗中枢神经系统囊尾蚴病患者脑脊液和血浆中吡喹酮水平的测定]

[Determination of praziquantel levels in cerebrospinal fluid and plasma in patients with cysticercosis of the central nervous system treated with praziquantel].

作者信息

Jia J Y

机构信息

Dept of Internal Medicine, 268th Hospital of PLA.

出版信息

Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1991 Jun;24(3):174-6, 189-90.

PMID:1889331
Abstract

The CSF and plasma concentrations of praziquantel (PZQ) were determined with high pressure liquid chromatography in 37 patients with cysticercosis of the central nervous system during a dosing regimen of PZQ 20 mg/kg p o q 8h for 3 days. The pharmacokinetic parameters were estimated using the nonlinear least squares method. The results showed that PZQ could pass through the blood-brain barrier. The absorption and elimination rates in CSF were slower than those in plasma, the corresponding mean levels being 0.1 and 0.27 micrograms/ml, which were lower than those in plasma. There was a linear correlation between CSF and plasma concentrations (r = 0.87, P less than 0.01). The neurological complications during the period of therapy were not related to the CSF level of PZQ. The cure rates of muscular and cerebral cysticerci were 14/14 and 5/37 respectively. The difference in susceptibility was considered to be caused by the pharmacokinetic behavior of PZQ and CSF and plasma. It was suggested that in general favorable regimens had better be adjusted with adequate increase of the dosage of PZQ, shortening the dosing interval, and prolong the period of PZQ treatment, but individualization of the PZQ dosing regiment would be necessary in accordance with the plasma concentration of the PZQ.

摘要

采用高压液相色谱法测定了37例中枢神经系统囊尾蚴病患者在口服吡喹酮(PZQ)20mg/kg、每8小时1次、共3天的给药方案期间脑脊液和血浆中PZQ的浓度。使用非线性最小二乘法估算药代动力学参数。结果显示PZQ能够透过血脑屏障。脑脊液中的吸收和消除速率比血浆中的慢,相应的平均水平分别为0.1和0.27微克/毫升,低于血浆中的水平。脑脊液和血浆浓度之间存在线性相关性(r = 0.87,P<0.01)。治疗期间的神经并发症与脑脊液中PZQ水平无关。肌肉和脑囊尾蚴的治愈率分别为14/14和5/37。易感性差异被认为是由PZQ以及脑脊液和血浆的药代动力学行为所致。建议一般而言,较好的治疗方案最好通过适当增加PZQ剂量、缩短给药间隔以及延长PZQ治疗时间来调整,但根据PZQ的血浆浓度对PZQ给药方案进行个体化调整是必要的。

相似文献

1
[Determination of praziquantel levels in cerebrospinal fluid and plasma in patients with cysticercosis of the central nervous system treated with praziquantel].[吡喹酮治疗中枢神经系统囊尾蚴病患者脑脊液和血浆中吡喹酮水平的测定]
Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1991 Jun;24(3):174-6, 189-90.
2
Preliminary report of praziquantel treatment of cysticercosis patients in Vietnam.越南吡喹酮治疗囊尾蚴病患者的初步报告。
Acta Leiden. 1989;57(2):229-33.
3
Plasma pharmacokinetics and therapeutic efficacy of praziquantel and 4-hydroxypraziquantel in Schistosoma japonicum-infected rabbits after oral, rectal, and intramuscular administration.吡喹酮和4-羟基吡喹酮经口服、直肠和肌肉注射给药后在日本血吸虫感染兔体内的血浆药代动力学及治疗效果
Am J Trop Med Hyg. 1992 May;46(5):582-8.
4
Plasma concentrations of praziquantel during the therapy of neurocysticerosis with praziquantel, in the presence of antiepileptics and dexamethasone.
Southeast Asian J Trop Med Public Health. 1995 Mar;26(1):120-3.
5
[Comparative analysis of the influence of food and cimetidine in plasma levels of praziquantel].
Rev Invest Clin. 2003 Nov-Dec;55(6):655-61.
6
[Cerebral cysticercosis treated with praziquantel--a case report].
No To Shinkei. 1994 Apr;46(4):381-6.
7
Penetration of praziquantel into cerebrospinal fluid and cysticerci in human cysticercosis.吡喹酮在人体囊尾蚴病中进入脑脊液及囊尾蚴的情况。
Eur J Clin Pharmacol. 1987;33(3):287-92. doi: 10.1007/BF00637564.
8
Pharmacokinetic optimisation of the treatment of neurocysticercosis.神经囊尾蚴病治疗的药代动力学优化
Clin Pharmacokinet. 1998 Jun;34(6):503-15. doi: 10.2165/00003088-199834060-00006.
9
Clinical pharmacokinetics of praziquantel.吡喹酮的临床药代动力学。
Proc West Pharmacol Soc. 1991;34:335-40.
10
Enhancement the oral bioavailability of praziquantel by incorporation into solid lipid nanoparticles.通过将吡喹酮载入固体脂质纳米粒提高其口服生物利用度。
Pharmazie. 2009 Feb;64(2):86-9.